Esperion Therapeutics (ESPR) Expected to Announce Quarterly Earnings on Tuesday

Esperion Therapeutics (NASDAQ:ESPR) is projected to issue its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of ($0.02) per share and revenue of $92.4770 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:00 AM ET.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.08). The firm had revenue of $80.10 million during the quarter, compared to analysts’ expectations of $84.52 million. Esperion Therapeutics had a negative return on equity of 0.14% and a net margin of 0.12%.

Esperion Therapeutics Stock Performance

Shares of ESPR remained flat at $3.18 during mid-day trading on Tuesday. Esperion Therapeutics has a fifty-two week low of $1.10 and a fifty-two week high of $4.18. The business’s fifty day moving average is $3.16 and its 200-day moving average is $2.99. The stock has a market capitalization of $819.45 million, a PE ratio of -53.00 and a beta of 1.07.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ESPR shares. HC Wainwright lowered Esperion Therapeutics from a “buy” rating to a “neutral” rating and set a $3.16 price objective for the company. in a report on Friday, May 1st. Jefferies Financial Group downgraded shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. Piper Sandler lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Tuesday, April 21st. Finally, Cantor Fitzgerald lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $5.54.

Insider Buying and Selling

In other Esperion Therapeutics news, insider Benjamin Looker sold 11,824 shares of the stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $3.15, for a total value of $37,245.60. Following the sale, the insider directly owned 667,524 shares in the company, valued at $2,102,700.60. This represents a 1.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Benjamin Halladay sold 10,773 shares of the firm’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $3.15, for a total transaction of $33,934.95. Following the completion of the transaction, the chief financial officer directly owned 702,829 shares of the company’s stock, valued at approximately $2,213,911.35. The trade was a 1.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Kestra Advisory Services LLC purchased a new stake in shares of Esperion Therapeutics in the fourth quarter worth $35,000. Captrust Financial Advisors purchased a new position in Esperion Therapeutics during the fourth quarter worth about $40,000. Cibc World Markets Corp bought a new position in Esperion Therapeutics in the 4th quarter worth about $57,000. Hudson Bay Capital Management LP bought a new position in Esperion Therapeutics in the 4th quarter worth about $67,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of Esperion Therapeutics in the 4th quarter valued at about $70,000. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.